75473-09-5 Usage
Uses
Used in Organic Chemistry:
2,3-Dichlorobenzoylacetonitrile is used as a reagent for the synthesis of various complex organic compounds. Its unique structure allows it to be a valuable intermediate in the preparation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
2,3-Dichlorobenzoylacetonitrile is used as a key intermediate in the synthesis of certain pharmaceutical compounds. Its reactivity and structural features make it a useful building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
2,3-Dichlorobenzoylacetonitrile is used as a starting material in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties enable the creation of effective compounds that can protect crops from pests and diseases.
Used in Specialty Chemicals:
2,3-Dichlorobenzoylacetonitrile is used as a precursor in the synthesis of specialty chemicals, such as dyes, pigments, and polymers. Its versatility in chemical reactions allows for the creation of a wide range of products with specific properties and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 75473-09-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,4,7 and 3 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 75473-09:
(7*7)+(6*5)+(5*4)+(4*7)+(3*3)+(2*0)+(1*9)=145
145 % 10 = 5
So 75473-09-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H5Cl2NO/c10-7-3-1-2-6(9(7)11)8(13)4-5-12/h1-3H,4H2
75473-09-5Relevant academic research and scientific papers
Pharmacologically active CNS compounds
-
, (2008/06/13)
The invention relates to compounds of formula (I) and salts thereof wherein R1 and R2 are the same or different and are each selected from hydroxy, or a group NR9R10 wherein R9 and R10 are each hydrogen, alkyl, aryl, arylalkyl or together with the nitrogen atom to which they are attached form a ring, optionally containing a further heteroatom and optionally further substituted by alkyl, aryl or arylalkyl;, R3 is selected from hydrogen, haloalkyl, alkyl and halo, R4 to R8 are the same or different, and are each selected from hydrogen, halo, nitro, amino, sulphonamido or alkylsulphonylamino;, or R4 and R5 or R5 and R6 may together form a carbocyclic ring;, with the proviso that at least one of R4 to R8 is other than hydrogen. The compounds may be used for the treatment or prophylaxis of a neurodegenerative or other neurological disorder of the CNS, the aetiology of which includes excessive release of the neurotransmitter glutamate.
